A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Medifast, Inc. (“Medifast,” the “Company,” “we” or “us”) is the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system. As we enter 2026, the Company is moving from transformation to execution, leveraging its extensive experience in structured weight loss coupled with recent scientific research and enhanced product offerings to address the needs of a broader metabolic health market. Medifast’s approach focuses on addressing the root cause of metabolic dysfunction. This strategic shift targets a larger and more sustainable market, focusing on a long-term growth strategy designed to guide the Company over the next decade by aligning science, products, and coaching with increasing demand for new solutions as awareness of metabolic dysfunction grows. This growth strategy is fueled by improving coach productivity and expanding our coach network.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 386M | 386M | 602M | 1.1B | 1.6B | 1.5B |
| Net Income | -19M | -19M | 2.1M | 99M | 144M | 164M |
| EPS | $-1.70 | $-1.70 | $0.19 | $9.10 | $12.73 | $13.89 |
| Free Cash Flow | 1.2M | 1.2M | 17M | 141M | 178M | 60M |
| ROIC | -10.2% | -9.4% | 3.3% | 48.4% | 93.0% | 81.1% |
| Gross Margin | 71.3% | 71.3% | 73.8% | 72.4% | 71.3% | 73.9% |
| Debt/Equity | 0.00 | 0.25 | 0.35 | 0.54 | 1.04 | 0.97 |
| Dividends/Share | $0.02 | $0.00 | $0.00 | $4.95 | $6.56 | $5.68 |
| Operating Income | -14M | -14M | 2.9M | 126M | 185M | 216M |
| Operating Margin | -3.7% | -3.7% | 0.5% | 11.8% | 11.6% | 14.2% |
| ROE | -9.4% | -9.1% | 1.0% | 49.3% | 92.6% | 81.0% |
| Shares Outstanding | 11M | 11M | 11M | 11M | 11M | 12M |
MEDIFAST INC passes 4 of 9 quality checks, suggesting mixed fundamentals.
On a free-cash-flow basis, the stock trades at 93.5x vs a median of 16.1x. The company's 5-year average ROIC is 43.3% with a gross margin of 72.5%. Total shareholder yield (dividends) is 0.2%. At current prices, the estimated annualized return to fair value is -18.9%.
MEDIFAST INC (MED) has a 5-year average return on invested capital (ROIC) of 43.3%. This indicates strong capital allocation and a potential competitive advantage.
MEDIFAST INC (MED) has a market capitalization of $117M. It is classified as a small-cap stock.
Yes, MEDIFAST INC (MED) pays a dividend with a trailing twelve-month yield of 0.17%.
MEDIFAST INC (MED) operates in the Miscellaneous Food Preparations & Kindred Products industry, within the Consumer Defensive sector.
MEDIFAST INC (MED) reported annual revenue of $386 million in its most recent fiscal year, based on SEC EDGAR filings.
MEDIFAST INC (MED) has a net profit margin of -4.8%. The company is currently unprofitable.
MEDIFAST INC (MED) generated $1 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
MEDIFAST INC (MED) has a debt-to-equity ratio of 0.25. This indicates a conservatively financed balance sheet.
MEDIFAST INC (MED) reported earnings per share (EPS) of $-1.70 in its most recent fiscal year.
MEDIFAST INC (MED) has a return on equity (ROE) of -9.1%. A negative ROE may indicate losses or negative equity.
MEDIFAST INC (MED) has a 5-year average gross margin of 72.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for MEDIFAST INC (MED), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MEDIFAST INC (MED) has a book value per share of $18.11, based on its most recent annual SEC filing.